While AstraZeneca's (AZN 2.31%) stock delivered solid returns in 2013, the company is still in the middle of a multiyear turnaround. With patent expirations just around the corner, and a pipeline that has failed to deliver a new blockbuster therapy in recent years, AstraZeneca's strategy has become the most important factor in its long-term survival in the pharmaceutical industry.
This massive company has several moving parts. But in the video below, Motley Fool analyst Max Macaluso focuses on just one red light and one green light that investors should consider before buying shares today.
